SG11201408641UA - Phenoxyethyl piperidine compounds - Google Patents
Phenoxyethyl piperidine compoundsInfo
- Publication number
- SG11201408641UA SG11201408641UA SG11201408641UA SG11201408641UA SG11201408641UA SG 11201408641U A SG11201408641U A SG 11201408641UA SG 11201408641U A SG11201408641U A SG 11201408641UA SG 11201408641U A SG11201408641U A SG 11201408641UA SG 11201408641U A SG11201408641U A SG 11201408641UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- indiana
- indianapolis
- company
- eli lilly
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 January 2014 (03.01.2014) WIPOIPCT (10) International Publication Number WO 2014/004229 A1 (51) International Patent Classification: C07D 211/60 (2006.01) A61P19/00 (2006.01) A61K31/45 (2006.01) A61P 29/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/046684 20 June 2013 (20.06.2013) English (30) Priority Data: 61/665,951 61/779,099 29 June 2012 (29.06.2012) 13 March 2013 (13.03.2013) English US US (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). (72) Inventors: SCHIFFLER, Matthew Allen; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). YORK, Jeremy Schulenburg; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (74) Agents: LENTZ, Nelsen L. et al.; ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206- 6288 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) (54) Title: PHENOXYETHYL PIPERIDINE COMPOUNDS C0 H 2 Formula II wherein X is: 0\ CJ CJ •t o o H C a , or O CJ o & (57) Abstract: The present invention provides a compound of the Formula II: Formula wherein II X is: R 1 is H, -CN, or F; R 2 is H or methyl; R 3 is H; and R is 4 H, methyl, or ethyl; or R 3 and R 4 joined together form a cyclopropyl ring; or a pharmaceutically accept able salt thereof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665951P | 2012-06-29 | 2012-06-29 | |
| US201361779099P | 2013-03-13 | 2013-03-13 | |
| PCT/US2013/046684 WO2014004229A1 (en) | 2012-06-29 | 2013-06-20 | Phenoxyethyl piperidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408641UA true SG11201408641UA (en) | 2015-01-29 |
Family
ID=48746666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408641UA SG11201408641UA (en) | 2012-06-29 | 2013-06-20 | Phenoxyethyl piperidine compounds |
Country Status (43)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3296B1 (en) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | Phenoxyethyl piperidine compounds |
| TWI636046B (en) * | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | Phenoxyethyl dihydro-1h-isoquinoline compounds |
| AU2014366361B2 (en) * | 2013-12-17 | 2017-04-20 | Eli Lilly And Company | Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators |
| CR20180323A (en) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | DERIVATIVES OF INDOL N-SUBSTITUTES AS MODULATORS OF PGE2 RECEIVERS |
| ES2929309T3 (en) | 2017-05-18 | 2022-11-28 | Idorsia Pharmaceuticals Ltd | Benzofuran and benzothiophene derivatives as PGE2 receptor modulators |
| ES2896476T3 (en) | 2017-05-18 | 2022-02-24 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| CA3060597A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as pge2 receptor modulators |
| EA039630B1 (en) | 2017-05-18 | 2022-02-18 | Идорсия Фармасьютиклз Лтд | N-substituted indole derivatives |
| AU2018268311B2 (en) | 2017-05-18 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| US20220064113A1 (en) * | 2019-01-22 | 2022-03-03 | Keythera (Suzhou) Pharmaceuticals Co. Ltd. | Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof |
| TW202228674A (en) | 2020-11-13 | 2022-08-01 | 日商小野藥品工業股份有限公司 | Cancer treatment with combination of ep4 antagonist and immune checkpoint inhibitor |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2500157C2 (en) | 1975-01-03 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | N-acyl-4- (2-aminoethyl) benzoic acids, their salts and esters, process for their preparation and their use |
| MXPA04005555A (en) * | 2002-03-18 | 2005-05-16 | Pfizer Prod Inc | Methods of treatment with selective ep4 receptor agonists. |
| BRPI0406717A (en) * | 2003-01-10 | 2005-12-20 | Hoffmann La Roche | Compound, pharmaceutical composition comprising the same, method of treating a disease in a mammal, use of the compound and process for its production |
| JP4116058B2 (en) * | 2003-09-03 | 2008-07-09 | ファイザー株式会社 | Phenyl or pyridylamide compounds as prostaglandin E2 antagonists |
| US20050105732A1 (en) * | 2003-11-17 | 2005-05-19 | Hutchings George T. | Systems and methods for delivering pre-encrypted content to a subscriber terminal |
| EA200601830A1 (en) | 2004-05-04 | 2007-04-27 | Пфайзер Инк. | ORT-SUBSTITUTED ARYL OR HETEROARYL AMIDAL COMPOUNDS |
| MXPA06011555A (en) * | 2004-05-04 | 2006-12-15 | Pfizer | Substituted methyl aryl or heteroaryl amide compounds. |
| US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| US7968578B2 (en) | 2006-04-24 | 2011-06-28 | Merck Frosst Canada Ltd. | Indole amide derivatives as EP4 receptor antagonists |
| WO2007143825A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
| WO2008092860A1 (en) * | 2007-01-30 | 2008-08-07 | Janssen Pharmaceutica N.V. | Bicyclic derivatives as ep4 agonists |
| BRPI0912778B1 (en) | 2008-05-14 | 2019-04-30 | Astellas Pharma Inc. | AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION UNDERSTANDING SAID COMPOUND AND USE OF THE SAME FOR THE TREATMENT OF CHRONIC RENAL FAILURE OR DIABETIC NEPHROPATHY |
| WO2010019796A1 (en) | 2008-08-14 | 2010-02-18 | Chemietek, Llc | Heterocyclic amide derivatives as ep4 receptor antagonists |
| RU2571816C2 (en) | 2010-02-22 | 2015-12-20 | Раквалиа Фарма Инк. | Using ep4 receptor antagonists in treating il-23-mediated diseases |
| HUE031408T2 (en) * | 2010-09-21 | 2017-07-28 | Eisai R&D Man Co Ltd | Pharmaceutical composition |
| ES2559513T3 (en) | 2011-07-04 | 2016-02-12 | Rottapharm Biotech S.R.L. | Cyclic amine derivatives as EP4 receptor antagonists |
| WO2013004291A1 (en) * | 2011-07-04 | 2013-01-10 | Rottapharm S.P.A. | Cyclic amine derivatives as ep4 receptor agonists |
| JO3296B1 (en) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | Phenoxyethyl piperidine compounds |
-
2013
- 2013-06-13 JO JOP/2013/0177A patent/JO3296B1/en active
- 2013-06-13 AR ARP130102076 patent/AR091429A1/en active IP Right Grant
- 2013-06-14 TW TW102121220A patent/TWI599561B/en active
- 2013-06-20 PT PT137342481T patent/PT2867207T/en unknown
- 2013-06-20 DK DK13734248.1T patent/DK2867207T3/en active
- 2013-06-20 SG SG11201408641UA patent/SG11201408641UA/en unknown
- 2013-06-20 BR BR112014031616-3A patent/BR112014031616B1/en active IP Right Grant
- 2013-06-20 HU HUE13734248A patent/HUE034425T2/en unknown
- 2013-06-20 ES ES13734248.1T patent/ES2644812T3/en active Active
- 2013-06-20 EP EP13734248.1A patent/EP2867207B1/en active Active
- 2013-06-20 AP AP2014008164A patent/AP2014008164A0/en unknown
- 2013-06-20 UA UAA201413598A patent/UA114325C2/en unknown
- 2013-06-20 AU AU2013280875A patent/AU2013280875B2/en active Active
- 2013-06-20 SI SI201330755T patent/SI2867207T1/en unknown
- 2013-06-20 ME MEP-2017-223A patent/ME02840B/en unknown
- 2013-06-20 LT LTEP13734248.1T patent/LT2867207T/en unknown
- 2013-06-20 PE PE2014002532A patent/PE20150182A1/en active IP Right Grant
- 2013-06-20 RS RS20171039A patent/RS56452B1/en unknown
- 2013-06-20 NZ NZ701933A patent/NZ701933A/en unknown
- 2013-06-20 WO PCT/US2013/046684 patent/WO2014004229A1/en active Application Filing
- 2013-06-20 MX MX2014015953A patent/MX345324B/en active IP Right Grant
- 2013-06-20 MA MA37686A patent/MA37686B1/en unknown
- 2013-06-20 JP JP2015520304A patent/JP6127136B2/en active Active
- 2013-06-20 CN CN201380034168.8A patent/CN104411684B/en active Active
- 2013-06-20 EA EA201492255A patent/EA024392B1/en not_active IP Right Cessation
- 2013-06-20 PL PL13734248T patent/PL2867207T3/en unknown
- 2013-06-20 MY MYPI2014703971A patent/MY173878A/en unknown
- 2013-06-20 KR KR1020147036137A patent/KR101653476B1/en active IP Right Grant
- 2013-06-20 CA CA2875569A patent/CA2875569C/en active Active
- 2013-06-20 US US13/922,278 patent/US8962659B2/en active Active
-
2014
- 2014-11-24 ZA ZA2014/08632A patent/ZA201408632B/en unknown
- 2014-11-27 CO CO14261550A patent/CO7151507A2/en unknown
- 2014-11-28 TN TN2014000501A patent/TN2014000501A1/en unknown
- 2014-12-03 CR CR20140553A patent/CR20140553A/en unknown
- 2014-12-11 IL IL236219A patent/IL236219A/en active IP Right Grant
- 2014-12-17 DO DO2014000287A patent/DOP2014000287A/en unknown
- 2014-12-17 GT GT201400288A patent/GT201400288A/en unknown
- 2014-12-26 CL CL2014003535A patent/CL2014003535A1/en unknown
- 2014-12-29 EC ECIEPI201433267A patent/ECSP14033267A/en unknown
-
2015
- 2015-01-05 PH PH12015500009A patent/PH12015500009A1/en unknown
- 2015-01-13 US US14/595,350 patent/US9402838B2/en active Active
- 2015-05-07 HK HK15104361.6A patent/HK1203937A1/en not_active IP Right Cessation
-
2017
- 2017-09-15 CY CY20171100979T patent/CY1119425T1/en unknown
- 2017-10-09 HR HRP20171515TT patent/HRP20171515T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201901197PA (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201408629QA (en) | Dimethyl-benzoic acid compounds | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| SG11201408261UA (en) | Syringe | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201403216UA (en) | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201408511QA (en) | Liquid preparations of amines and organic acids stabilized by salts | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201402986RA (en) | Kinase inhibitors | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto |